Compare Novartis AG (NVS) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: Novartis AG pays a 3.02% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and Novartis AG is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVS | SGOV | |
|---|---|---|
Market Cap | $298.18B | — |
Sector | Health | Fixed Income |
52-Week High | $168.62 | $100.74 |
52-Week Low | $119.31 | $100.28 |
Enterprise Value | $339.50B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.48, showing minimal daily movement. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights institutional stake adjustments and investor interest in ultra-short Treasury ETFs as a defensive pivot amid market volatility, with articles noting its role as a conservative cash alternative offering a yield around 3.8% (Seeking Alpha, 2026-08-03).
The ETF provides exposure to short-term U.S. Treasury bills, benefiting from rising interest rates but facing risks from Federal Reserve policy uncertainty and inflation data. Its principal protection and monthly distributions appeal to risk-averse investors, though price appreciation is limited by its nature. Key risks include interest rate changes and macroeconomic shifts influencing Treasury yields.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
